Crohn's disease

New challenges, opportunities in autoimmune disease treatment
New challenges, opportunities in autoimmune disease treatmentAllegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.
Game changing idea: Specialty intensive medical homeBlue Cross Blue Shield of Illinois partners with gastroenterology group to focus on Crohn’s disease patients.
Clinical team alignment top priority for payersInvestment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives.
Why Remicade biosimilar sales will grow in the U.S.Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
Positive results found for biosimilar in treating psoriasis patientsThe biosimilar candidate ABP 501 (Amgen) has proved to be successful in treating patients with moderate-to-severe plaque psoriasis, according to results from an initial phase 3 study. ABP 501 met its primary end point for efficacy.